19.01.2022 14:50
With 147 spin-off companies created, the University of Zurich remains a fertile group for researchers to transform their ideas into a business. Last year, four new spin-offs focusing on biopharmaceuticals and biomedicine emerged after signing a licensing agreement with UZH. The spinoffs are developing new products or therapies, including a device that tests the quality of donor organs, a drug that combats depression and anxiety, and one to treat malignant tumours as well as immunotherapies to combat cancer.